Department of Pharmacology and Pharmacotherapy, Section for Social Pharmacy, Faculty of Pharmaceutical Sciences, University of Copenhagen, FKL-Research Centre for Quality in Medicine Use, Copenhagen, Denmark.
Br J Clin Pharmacol. 2011 May;71(5):751-7. doi: 10.1111/j.1365-2125.2011.03915.x.
To identify adverse drug reactions (ADRs) associated with off-label prescribing of medicines in a paediatric population.
We analysed spontaneous ADR reports for children from ages 0 to 17 years submitted to the Danish national ADR database from 1998 to 2007. We defined off-label prescribing as prescriptions outside the licensed age group. Off-label ADRs were categorized by therapeutic group, age of child, type and severity. The unit of analysis was one ADR.
We analysed 4388 ADRs for children reported in the national database. Approximately 17% of reported ADRs were associated with off-label use, 60% of them serious. More than one half of off-label ADRs were reported in adolescents. Serious ADRs due to off-label prescribing are more likely to be reported for hormonal contraceptives (ATC group G), anti-acne preparations (ATC group D) and allergens (ATC group V).
One-fifth of all ADRs reported over a decade in Danish children was associated with off-label prescribing, and serious ADRs due to off-label prescribing were primarily present in three therapeutic groups: sex hormones, dermatologicals and allergens. There is a need for more research into the prescribing of these medicines in the teenage population, as well as tighter reporting and monitoring of ADRs for medicines prescribed off-label in the paediatric population.
确定儿科人群中药物超说明书使用相关的不良反应(ADR)。
我们分析了 1998 年至 2007 年期间丹麦国家 ADR 数据库中提交的 0 至 17 岁儿童自发 ADR 报告。我们将超说明书处方定义为超出许可年龄组的处方。根据治疗组别、儿童年龄、类型和严重程度对超说明书 ADR 进行分类。分析单位为一个 ADR。
我们分析了国家数据库中报告的 4388 例儿童 ADR。约 17%的报告 ADR 与超说明书使用有关,其中 60%为严重 ADR。超过一半的超说明书 ADR 发生在青少年中。由于超说明书处方而导致的严重 ADR 更可能与激素避孕药(ATC 组 G)、抗痤疮制剂(ATC 组 D)和过敏原(ATC 组 V)有关。
丹麦儿童在十多年中报告的所有 ADR 中,有五分之一与超说明书处方有关,由于超说明书处方而导致的严重 ADR 主要存在于三个治疗组别:性激素、皮肤科药物和过敏原。需要对青少年人群中这些药物的处方进行更多研究,并加强对儿科人群中超说明书处方药物 ADR 的报告和监测。